Lyudmila Mateva

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH

Sven Francque, Pierre Bédossa, Vlad Ratziu et al. · New England Journal of Medicine · 2021 · 721 citations · Full text

Medicine, Internal Medicine, Pharmacology +15

A global research priority agenda to advance public health responses to fatty liver disease

Henry E. Mark, Alina M. Allen, Juan Pablo Arab et al. · Journal of Hepatology · 2023 · 132 citations · Full text

Public Affairs, Health Policy, Epidemiology +12

Liquid chromatography method for simultaneous analysis of amino acids and biogenic amines in biological fluids with simultaneous gradient of pH and acetonitrile

Valentin Lozanov, Bistra Benkova, Lyudmila Mateva et al. · Journal of Chromatography B · 2007 · 49 citations

Pharmacy, Biochemistry, Analytical Chemistry +12

Historical epidemiology of hepatitis C virus in select countries—volume 4

Abderrahmane Maaroufi, Adriana Vince, Sayed Himatt et al. · Journal of Viral Hepatitis · 2017 · 39 citations · Full text

Medicine, Health Policy, Infectious Diseases +17

Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor

Dorien Groenendaal‐van de Meent, Martin den Adel, Jan Noukens et al. · Clinical Drug Investigation · 2016 · 38 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17